Overview

Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant

Status:
Terminated

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

The study is undertaken to explore the safety of using Simulect at monthly dose intervals to reduce the need of high dose/level CNI's such as Prograf.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Drexel University College of Medicine

Collaborator:

Novartis

Treatments:

Antibodies, Monoclonal
Basiliximab